KRT88P and diffuse large B-cell lymphoma: Between January 2018 and April 2021, 55 R/R DLBCL patients received BTKi-containing therapy, 4 of whom had chronic HBV infection (HBsAg positive), 26 with resolved HBV infection (HBsAg negative and anti-HBc positive) and 25 without HBV infection (Figure 1; Table 1).